Program

HomeProgram ▶ Virtual Industry Programs
Virtual Industry Programs

Enhance your educational experience during ATS 2020 Virtual by listening to industry experts discuss the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine. There are 20 programs throughout August 5-9 between 1-2 p.m. EDT and 5:30-6:30 p.m. EDT with programs lasting 30 or 60 minutes. During this time, industry programs vary in format – on-demand or live with Q&A. Do not miss one single innovative presentation! The programs are also accessible at your leisure on the ATS 2020 Virtual platform until November 10.


Type 2 Inflammation in Asthma, CRSwNP, NSAID-ERD, and COPD

Sponsored by Sanofi Genzyme and Regeneron
Live and available on-demand, 1-2 p.m. EDT | Open to all attendees
Topic: Asthma

Hear experts review Type 2 inflammation as an underlying disease process that contributes to frequently coexisting conditions. Our experts will review current literature on key cytokines or IL-4/IL-13, which contribute to the key components of Type 2 inflammation: allergic inflammation, eosinophilic inflammation, and epithelial barrier dysfunction. In addition, the implications of coexisting Type 2 inflammatory diseases, such as greater disease severity and worse disease control, will be reviewed.

Speakers:

  • William J. Calhoun MD, Professor of Internal Medicine, Pulmonary, Allergy, and Clinical Immunology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
  • Monica Kraft, MD, Professor, Medicine, Chair, Department of Medicine, UA Health Sciences Asthma and Airway Disease Research Center, Tuscon, AZ

ISABELA - how to execute the largest Phase 3 program in IPF to date

Sponsored by Gilead Sciences & Galapagos
On-Demand, 1 - 1:30 p.m. EDT | Open to all attendees
Topic: Idiopathic Pulmonary Fibrosis (IPF)

The ISABELA clinical trial programe is planned to be the largest phase 3 programme performed in patients with IPF to date, globally recruiting 1,500 patients in a rare disease population. This presentation will showcase the innovative and agile ways in which Galapagos have responded to the needs of patients and investigators to ensure the successful execution of these trials.

Speaker:

  • Paul Ford, MD PhD, Galapagos

Understanding the Role of Type 2 Inflammation in Airway Diseases: Interconnections and Interdisciplinary Considerations

Sponsored by Regeneron and Sanofi Genzyme
Live and Available On-Demand, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: Asthma

While inflammatory airway diseases are heterogeneous, Type 2 inflammation is a common underlying pathophysiology in many affected patients. In particular asthma and CRSwNP, two airway diseases that are predominantly driven by Type 2 inflammation, pose a substantial burden to patients, which is further increased when these diseases coexist. An understanding of Type 2 inflammation in asthma, a lower airway disease and CRSwNP, an upper airway disease, and the interactions between them, is imperative to reducing disease burden and improving control. This program will review the importance of Type 2 inflammation in asthma and CRSwNP, including their shared pathophysiology, the role of key Type 2 cytokines and why management of these diseases must involve interdisciplinary approaches and considerations.

Speakers:

  • William W. Busse, MD, Professor of Medicine, Allergy,Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health Madison, Wisconsin
  • Kenneth R. Chapman, MD, MSc, Professor of Medicine, Director of the Asthma and Airway Centre, University of Toronto, University Health Network, Toronto, Canada
  • Jivianne T. Lee, MD, Associate Professor, Rhinology & Endoscopic Skull Base Surgery, Department of Head & Neck Surgery, UCLA David Geffen School of Medicine, Los Angeles, California

The Current State of OFEV® (nintedanib): A Treatment Journey

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Live and Available On-Demand, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: Interstitial Lung Disease (ILD)

The program will review background information followed by the most up-to-date data supporting the efficacy and safety of OFEV.

Speaker:

  • Paul W. Noble, MD, Professor and Chair, Department of Medicine, Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine, Director, Women's Guild Lung Institute, Physician-in-Chief, Cedars-Sinai Medical Center, Los Angeles, CA

Clinical Perspectives on COPD Maintenance Treatment Approaches with Dual Bronchodilator and Triple Therapy

Sponsored by GlaxoSmithKline (GSK)
Live, 1 - 2 p.m. EDT | Open to U.S. attendees only
Topic: COPD

Intended for US Healthcare Professionals Only - Join leaders in the field Dr. Sanjay Sethi and Dr. Tom Corbridge as they take a closer look at the Head-to-Head clinical evidence supporting the use of a dual bronchodilator or a triple therapy maintenance treatment approach for patients with COPD.

Speakers:

  • Sanjay Sethi, MD, FACP, Professor, Assistant Vice President of Health Services, Division Chief, Pulmonary, Critical Care and Sleep Medicine, Jacobs School of Medicine & Biomedical Sciences, University of Buffalo
  • Tom Corbridge, MD, FCCP, US Medical Expert, Respiratory, GSK

Severe Eosinophilic Asthma: Case Studies With a Targeted Treatment Approach

Sponsored by AstraZeneca
On-Demand, 1 - 2 p.m. EDT | Open to all attendees
Topic: Asthma

You are cordially invited to view a pre-recorded program to learn about the clinical impact of a targeted biologic treatment option on exacerbations and lung function in patients with severe eosinophilic asthma. Listen to an expert to explore its clinical efficacy, mechanism of action, and safety profile data.

Speaker

  • Donna Carstens, MD, Pulmonary Medicine, Sr. Medical Director, Fasenra, AstraZeneca

The Role of Type 2 Inflammation in Asthma and Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Sponsored by Sanofi Genzyme and Regeneron
Live and Available On-Demand, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: Asthma

Asthma and CRSwNP often coexist due to overlapping pathobiological mechanisms associated with Type 2 inflammation. During this presentation, experts will present data reported from 2 distinct clinical development programs in asthma and CRSwNP.

  • Geoffrey Chupp, MD, Professor of Medicine, Yale School of Medicine, New Haven, CT
  • Laren Tan, MD, Associate Professor, Loma Linda University Health, Loma Linda, CA

A New Direction in PAH: A Potential Therapy for Rebalancing BMPR2 Signaling

Sponsored by Acceleron Pharma
Live and Available On-Demand, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: Pulmonary Arterial Hypertension (PAH)

Despite multiple treatment options, patients with PAH still face a devastating and progressive disease. This program will focus on the imbalances in BMPR2 and activin receptor signaling that may drive PAH progression. A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential disease modification.

Speaker:

  • Vallerie McLaughlin, MD, University of Michigan, Ann Arbor

Evidence and Insights for Using a Biologic to Manage Severe Eosinophilic Asthma

Sponsored by GlaxoSmithKline (GSK)
Live, 1 - 2 p.m. EDT | Open to U.S. attendees only
Topic: Severe Asthma

Please join an expert panel of physicians for a case-based discussion on severe eosinophilic asthma and approaches to help identify and manage patients. Clinical evidence supporting the use of a targeted biologic therapy will be reviewed, including data from long-term and real-world studies. In addition, the panel will provide practical insights to help inform management of patients with severe eosinophilic asthma. Engagement with the panel is encouraged through live Q&A at the conclusion of the program.

Speakers:

  • Ronald Balkissoon, MD, Pulmonary Consultant, Department of Pulmonary Medicine, National Jewish Health
  • Maeve O'Connor, MD, Medical Director and Founder Allergy, Asthma, & Immunology Relief, Allergy, Asthma and Immunology Research Institute
  • Thomas Corbridge, US Medical Expert, Respiratory, GSK

Acthar (R) Gel (repository corticotropin injection): Retrospective Analysis Study (N=302)

Sponsored by Mallinckrodt Pharmaceuticals
Live, 1 - 1:30 p.m. EDT | Open to U.S. attendees only
Topic: Sarcoidosis

This program will provide an engaging discussion on large recently published sarcoidosis data led by Dr. Dasgupta.

  • Identification of advanced sarcoidosis
  • The burden and mechanism of disease of sarcoidosis and the proposed mechanism of action of Acthar Gel
  • A review of recently published Retrospective Analysis of 302 patients

Speaker:

  • Raj Dasgupta, MD, FACP, FCCP, FAASM, Assistant Professor of Clinical Medicine; Assistant Program Director of Internal Medicine Residency Associate Program Director of Sleep Medicine Fellowship Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine of USC University of Southern California Department of Medicine

Reclassifying risk of malignancy in indeterminate pulmonary nodules using the Nodify Lung™ testing strategy.

Sponsored by Biodesix, Inc.
Live and Available On-Demand, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: Lung Cancer/Lung Disease

This program will provide an overview of the Nodify Lung testing strategy, discuss case studies using the Nodify CDT™ and Nodify XL2™ tests and share recent data published from the ORACLE clinical study and real-world clinical use.

Dr. Pritchett will discuss how the testing strategy helps identify patients with a higher risk of malignancy who may be considered for timely intervention and those with a lower risk of malignancy who may be considered for CT surveillance.

Speaker:

  • Michael Pritchett, DO, MPH, Director of Thoracic Oncology, Pulmonary and Critical Care Physician, President of the Society for Advanced Bronchology, Firsthealth of the Carolinas, and Pinehurst Medical Clinic

Ventilatory Support during COVID-19

Sponsored by Philips
On-Demand, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: COVID-19

This presentation will present guidelines and clinical observations for respiratory management of COVID-19 with a focus on current aspects of ventilation.

Speaker:

  • Adam Seiver, MD, Chief of Medical Affairs, Philips

Treatable Traits Approach Towards COPD Management for Busy Pulmonologists

Sponsored by GlaxoSmithKline (GSK)
Live, 1 - 2 p.m. EDT | Open to U.S. attendees only
Topic: COPD

With the GOLD 2020 strategy document, the focus on utilization of the treatable traits approach of symptoms and exacerbations for COPD management continues to gain prominence. This program will provide a concise update for busy pulmonary practitioners using a case based approach with a focus on the implementation of the concepts of this treatable traits approach in COPD management.

Speakers:

  • Carolyn Rochester, MD, Professor of Medicine and Medical Director of the Yale COPD Program, Yale University School of Medicine and Medical Director of the Pulmonary Rehabilitation Program, VA Connecticut Healthcare System, Yale New Haven Hospital
  • Nadia Hansel, MD, MPH, Associate Dean of Research, Johns Hopkins Bayview and Professor of Medicine, The Johns Hopkins Hospital

Acthar (R) Gel (repository corticotropin injection): Retrospective Analysis Study (N=302)

Sponsored by Mallinckrodt Pharmaceuticals
Live, 1 - 1:30 p.m. EDT | Open to U.S. attendees only
Topic: Sarcoidosis

This program will provide an engaging discussion on large recently published sarcoidosis data led by Dr. Ayinla.

  • Identification of advanced sarcoidosis
  • The burden and mechanism of disease of sarcoidosis and the proposed mechanism of action of Acthar Gel
  • A review of recently published Retrospective Analysis of 302 patients

Speaker:

  • Raji Ayinla, MD, CMD, FCCP, FACP, Chief of Pulmonary/Critical Care; Chairman, Department of Medicine; and Program Director, Internal Medicine Residency Training Program, NYC Health + Hospitals/Harlem, New York, NY; Medical Director, Harlem Center for Nursing and Rehabilitation, New York, NY; Assistant Professor of Medicine, Columbia University College of Physicians & Surgeons and Mount Sinai School of Medicine, New York, NY

Idiopathic Pulmonary Fibrosis (IPF) Differential Diagnoses: Utilizing Radiologic Findings to Determine a Specific Diagnosis

Sponsored by Genentech, a Member of the Roche Group
Live, 5:30 - 6 p.m. EDT | Open to U.S. attendees only
Topic: Idiopathic Pulmonary Fibrosis (IPF)

A radiologist-led discussion on identifying unique radiologic patterns for interstitial lung diseases to arrive at the differential diagnosis of IPF.

Speaker:

  • Tadashi Allen, MD, Assistant Professor Of Radiology; Section Chief, Thoracic Imaging, Body Imaging Division, University of Minnesota, Minneapolis, MN

Nontuberculous Mycobacterial Lung Disease: Optimizing Diagnosis and Management to Improve Outcomes

A non-CME educational program sponsored by Vindico Medical Education and supported by a grant from Insmed Incorporated

Live and Available On-Demand, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: Nontuberculous Mycobacteria (NTM)

Join us as our faculty review up-to-date knowledge of nontuberculous mycobacteria (NTM) epidemiology and pathogenesis and provide guidance on use of appropriate diagnostic criteria. We will also discuss evidence-based approaches to manage NTM pulmonary disease and strategies for applying the latest clinical data when selecting therapy for refractory disease.

Speakers:

  • Anne O'Donnell, MD, Professor of Medicine; Chief, Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Medical Center
  • Kevin Winthrop MD, MPH, Professor, Division of Infectious Diseases Schools of Medicine and Public Health, Oregon Health and Sciences University

Exploring Idiopathic Pulmonary Fibrosis (IPF) With the Experts: A Case-Based, Multidisciplinary Program on the Differential Diagnosis and Management of IPF

Sponsored by Genentech, a Member of the Roche Group
Live, 1 - 2 p.m. EDT | Open to U.S. attendees only
Topic: Idiopathic Pulmonary Fibrosis (IPF)

Join our multidisciplinary experts for an engaging case-based program on the intricacies of IPF. This program will explore the pragmatic steps to the differential diagnosis of IPF, leveraging radiology, with a focus on imaging nuances, and initiating and maintaining a comprehensive management plan that features an FDA-approved IPF-specific therapy.

Speakers:

  • Steven D. Nathan, MD, Medical Director, Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA
  • Alison G. Wilcox, MD, Vice Chief of Staff, Keck Medical Center; Professor of Clinical Radiology and Internal Medicine; Medical Director, Imaging, Keck Hospital of USC, Los Angeles, CA

Clinical Overview of SUNOSI and a Patient Case Study

Sponsored by Jazz Pharmaceuticals
Live and Available On-Demand, 1 - 1:30 p.m. EDT | Open to U.S. attendees only
Topic: Obstructive Sleep Apnea (OSA)

Join your fellow healthcare professionals for an engaging presentation including:

  • The burden and mechanism of disease of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA)
  • An overview of the clinical efficacy and safety of SUNOSI
  • A clinical case to help identify patients who may be candidates for SUNOSI

Speaker:

  • Richard E. Friedenheim, MD, Medical Director, Abington Sleep Disorders Center, Abington Pulmonary and Critical Care Associates, Abington Hospital - Jefferson Health

Sounding the Alarm: The Role of TSLP Across the Spectrum of Asthma Inflammation

Sponsored by Amgen/AstraZeneca
Live and Available On-Demand, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: Asthma

There’s a new way to think about asthma and it starts at the top of the inflammatory cascade. Join us as an expert explores the role of a key epithelial cytokine, thymic stromal lymphopoietin (TSLP), in driving multiple downstream inflammatory pathways.

Speaker:

  • Michael Wechsler, MD, Pulmonologist, National Jewish Health

Optimizing the Care of Patients with Progressive-Fibrosing Interstitial Lung Disease: Applying the Latest Data

A non-CME educational program sponsored by Vindico Medical Education and supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Live and Available On-Demand, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: Progressive Fibrosing - Interstitial Lung Disease (PF-ILD)

Join us for a non-CME virtual program to review the latest guidelines and evidence for diagnosing and treating progressive fibrosing interstitial lung disease (PF-ILD). This educational activity will emphasize the importance of treatment adherence and effective multidisciplinary approaches to improve the quality of care for your patients. We will discuss clinical cases focused on integrating optimal diagnostic and therapeutic approaches into practice.

Speakers:

  • Steven D. Nathan, MD, Medical Director, Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital
  • Kevin R. Flaherty, MD, Professor of Medicine Division of Pulmonary/Critical Care Medicine Director, Michigan Medicine Interstitial Lung Disease Clinic, University of Michigan